STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   Kent Jeff
   C/O HORIZON THERAPEUTICS PLC
   CONNAUGHT HOUSE, 1ST FL., 1 BURLINGTON RD
   DUBLIN L2 4

2. Issuer Name and Ticker or Trading Symbol
   Horizon Therapeutics Public Ltd Co [ HZNP ]

5. Relationship of Reporting Person(s) to Issuer
   Director
   10% Owner

3. Date of Earliest Transaction (Month/Day/Year)
   01/03/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)
   Form filed by One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 4)</th>
<th>5. Securities Acquired (A) or Disposed Of (D) (Instr. 4)</th>
<th>6. Securities Acquired (A) or Disposed Of (D) (Instr. 4)</th>
<th>7. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>8. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>9. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary Shares</td>
<td>01/05/2020</td>
<td></td>
<td>M</td>
<td>A (1)</td>
<td>14,873</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>Ordinary Shares</td>
<td>01/05/2020</td>
<td></td>
<td>F</td>
<td>D</td>
<td>6,776</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>Ordinary Shares</td>
<td>01/07/2020</td>
<td></td>
<td>G(2)</td>
<td>D</td>
<td>3,545</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 4)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 4)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Units (RSU)</td>
<td>(1)</td>
<td>01/03/2020</td>
<td>A</td>
<td>29,027</td>
<td>(4)</td>
<td>(4) Ordinary Shares 29,027 0.00 29,027 D</td>
<td>D</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>Restricted Stock Units (RSU)</td>
<td>(1)</td>
<td>01/05/2020</td>
<td>M</td>
<td>6,700</td>
<td>(5)</td>
<td>(5) Ordinary Shares 6,700 0.00 6,700 D</td>
<td>D</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>Restricted Stock Units (RSU)</td>
<td>(1)</td>
<td>01/05/2020</td>
<td>M</td>
<td>8,173</td>
<td>(6)</td>
<td>(6) Ordinary Shares 8,173 0.00 16,348 D</td>
<td>D</td>
<td>D</td>
<td>D</td>
<td>D</td>
</tr>
</tbody>
</table>

Explanations of Responses:
1. Each RSU represents a contingent right to receive one ordinary share of the Issuer.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 23, 2019.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.51 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The RSU's vest 1/3rd annually on each anniversary of January 5, 2018.
6. The RSU's vest 1/3rd annually on each anniversary of January 5, 2019.

Remarks:
Officer Title: SVP, Head of Medical Affairs & Outcomes Research.

/s/ Miles W. McHugh
Attorney-in-Fact
01/07/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.